Author: Andrew Powrie-Smith Date: 05/04/2016 Version: draft

Disease Diagnosis enables a targeted approach to personalised medicines that has Resulted in decreased death rates from cancer

Note: WHO Mortality Database age-standardized death rates per 100,000 for malignant neoplasm of trachea, bronchus and lung.
Source: Health Advances analysis; 1WHO Mortality Database (accessed February 2016); 2My Cancer Genome website – Molecular Profiling of Lung Cancer; 3Pao 2012 Chipping away at the lung cancer genome Nat Med.
Identified Mutations/Rearrangements over Time2,3
The evolution of molecular characterization and targeted therapeutics has led to a decrease in the average lung cancer death rate in the United Kingdom by 37% since 1980
2000
1980
Adenocarcinoma
2012
2007
45.1 deaths per 100,000
32.6 deaths per 100,000
30.5 deaths per 100,000
28.4 deaths per 100,000
Age-standardized death rates per 100,000 world standard population over time1
0 identified
1 identified
5 identified
12 identified

Biopharmaceutical Companies Have Made continued advances against rare diseases

Biopharmaceutical Companies Have Made continued advances against rare diseases

Source: Health Advances analysis; 1PhRMA 2013 Rare Diseases Report
Source: Alexis Schimmings, New active substances launch plummet , Scrip Intelligence Unit. Available at : http://www.scripintelligence.com/home/New-Active-Substance-Launches-Plummet-363577
There are approximately 7,000 different rare diseases worldwide
Rare Disease
Big Impact
1 in 10 individuals in the USA and Europe are living with a rare disease1
Percentage of New Active Substances launched with orphan drug status 2012-2015
Today more than 7000 medicines
Are in Development Around the World Targeting Areas of High Unmet Need